伐地那非治疗勃起外周（ED）

阴部紊乱（ED）病变愈来愈比如说常用Vardenafil（兴兵地那非）开展外科开刀对ED用药Sildenafil（西地那非）和Vardenafil（兴兵地那非）开展比如说比较实验，期望必需获取无偏见的结果。波士顿-2006年9月20日，研究成果结果刊发在《适度Medicine》上，同时在埃及巴格近成席会议的适度医学国际协会第十二届大会上发表。这项研究成果非常多样，因为其图表来自一项关于PDE5（磷酸二脂复合物5）诱导用药的如此一来对比临床研究成果试验中，该试验中常用PDE5诱导用药来外科开刀ED病变。整个研究成果经过精心设计使得针对每种用药的偏见近到最小化。这是一项随机、双盲、交叉和如此一来对比的临床研究成果试验中，常用西地那非和兴兵地那非外科开刀患有ED、乳胃癌、腹水和/或高血脂的男适度病变，比较了二者的治果。结果推断在数个常用的确实所高效率上兴兵地那非取得了统计学意义上的占到有优势，在病者忠诚度和比如说适度的多个评估试验中中都，兴兵地那非的平庸并不比西地那非差。分别为1，057名男适度参加了这项研究成果，他们首先连续四个月内口服一种用药，然后是一个月内时间的缓冲期，接着再连续四个月内口服另一种用药。病者会被问道这样的问题：“总的来说，你愈来愈喜欢常用那种用药？”此外还有其他11个有关ED外科开刀的问题。利用预定标准化开展预设确实评估在研究成果中都也被常用。图表推断38.9%的病者比如说常用兴兵地那非，而34.5%的病者愿意常用西地那非（26.6%的病者无比如说适度）。在阴部机能，忠诚度和上都忠诚度方面，兴兵地那非很大优于西地那非。在阴部时填入硬度，阴部持续时间，五小持续和阴部信心方面，兴兵地那非也有愈来愈高比例的阳适度反应。这项研究成果的一同笔记，适度Medicine的主编Irwin Goldstein 理解说：“该研究成果暗示我们对PDE5诱导用药临床研究成果差异的认知又前进了助于要一步，肯定了兴兵地那非外科开刀ED的。”以外有三种PDE5诱导用药可用作外科开刀ED，它们分别是西地那非，他近那非和兴兵地那非。根据研究成果者的说法，所有这三种用药对一定区域内的年轻人都平庸成确实和抗适度。来自如此一来对比的临床研究成果实验图表（如本项研究成果）非常稀少，然而这样的研究成果结果会帮助临床研究成果医生对西地那非、兴兵地那非和他近那非加以差异以选择最适合的用药供个体病病变常用。文化背景知识：ED：阴部紊乱 Erectile dysfunction, ED是所指持续不用近到或者持续阴部以满足。ED比过去用的"阳萎"（Impotence）一词愈来愈确切，因为腹水一词带有一定歧适度的意味。ED可按其程度包含轻、中都、助于三度，腹水总称助于度的ED。70中期后由于阴部环境因素和解剖研究成果的十分困难，人们坚信固然恐惧因素确实可以激起ED，但对大多数男适度来说，ED与许多性疾病（腹水，乳胃癌，心胃药疾病）、用药、手部及开刀等有关，因为阴部机能是腹膜消化道肿胀，横膈膜扩大张，血引增加和脊柱回引受阻等比较简单血液物理现象全过程，在这一全过程中都，任何紊乱的病因可以包含： 器质适度ED 血管适度状况：包括任何不太可能引发腹膜横膈膜血引减缓的性疾病，如：横膈膜粥样凝固，横膈膜细菌感染，横膈膜宽广，横膈膜分引及心机能出现异常等，或放任脊柱回引闭合机能的白膜、海绵窦内消化道减缓所致的脊柱断。 神经适度状况：中都枢、则有神经性疾病或细菌感染均可以引发阴部紊乱。 开刀与手部：大血管开刀、胃癌根治术、腹会阴直肠胃癌根治术等开刀及骨盆左腿、腰椎压缩适度左腿或骑跨伤，可以激起起有关的血管和神经细菌感染，引发阴部紊乱。 遗传性强迫症、慢适度病和长期口服某些用药也可以激起阴部紊乱。 本身性疾病：如硬结症（Peyronie's disease）、弯曲发育不良、严助于包茎和阴道捕猎药。 恐惧适度ED 所指紧张、压力、抑郁、恐惧和夫妻感情不和等自觉恐惧因素所造成了的阴部紊乱。 混合适度ED 所指自觉恐惧因素和器质适度病因一同引发的阴部紊乱。此外，由于器质适度ED未曾获取幸而的外科开刀病变后遗症加助于，害怕失败，使ED外科开刀愈来愈加趋向复杂。国内都由628例ED病变病因定义的研究成果暗示：恐惧适度占到39%。器质适度为15.8%，混合适度占到45.2%。PDE5诱导剂PDE5是腹膜中都消化道细胞内第二信使NO-cGMP的分解复合物。PDE5诱导剂必需增加cGMP的溶解度，增强腹膜消化道的舒张作用，并推动适度刺激诱发的阴部反应。PDE5诱导剂类用药对ED外科开刀具有最普遍的确实和抗适度。因此，该类用药被看做口服外科开刀用药的概要标准化。以外，该类用药包括三种：西地那非、兴兵地那非和他近的卡非。西地那非在1998年，兴兵地那非和他的卡那非则是在2003年获取全球认证。在临床研究成果常用以及临床研究成果相异研究成果中都发现，PDE5诱导剂具有更佳的抗适度和确实。在一般而言ED病变中都，临床研究成果研究成果充分证实上述三种用药的确实。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON ---- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.校对：bluelove

校对： Zhu